The market was estimated at USD XX million in 2015 and is expected to reach USD XX million by 2021, growing at a CAGR of X% during the forecast period 2016 to 2021.
The acute lymphoblastic leukemia (ALL) is commonly called as lymphoblastic leukemia. This cancer originates from the early stage of white blood cells, known as lymphocytes, in the bone marrow. It spreads to other parts of the body, such as lymph nodes, liver, spleen, central nervous system, and other body parts. ALL is the most common type of cancer during childhood.
As per the American Cancer Society estimates, 6,590 new cases of ALL and 1,430 deaths are expected in 2016, due to ALL in the United States itself. Cancer Research UK noted 818 new cases of ALL, in 2013. The National Cancer Institute USA, states that nearly 68.1% patients survive for five years. New product launches, increasing clinical studies on ALL, and increasing access to drugs in emerging economies are propelling the growth of the market.
Acute Lymphoblastic Leukemia Therapeutics - Market Dynamics
The key factors propelling the growth of the market are -
The factors restraining the market are -
The market has been segmented based on chemotherapy and geography. The chemotherapy segment includes CALGB 8811 regimen, hyper – CVAD regimen, Oncaspar, linker regimen, nucleoside inhibitors, and others. Geographically the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
The key players in the market are
What the Report Offers
Looking to Customize Report?